Archives
-
Lamotrigine Assay Design for Neural and Cardiac Studies
2026-09-17
Discover how Lamotrigine can support rigorous sodium-channel, serotonin, epilepsy, and cardiac research. This guide converts metabolic-assay lessons from a sumatriptan study into practical controls for interpreting Lamotrigine pharmacology without overextending the evidence.
-
SHH, FGF10, and Species-Specific Penile Development
2026-09-17
A 2025 comparative study identifies differential Shh, Fgf10, and Fgfr2 expression as a functional explanation for why guinea pigs form an open urethral groove whereas mice primarily canalize a urethral plate. By combining spatial expression analysis, quantitative PCR, and genital-tubercle culture, the work connects pathway dosage and developmental timing with preputial and urethral morphogenesis.
-
Trelagliptin and PI3K/AKT Signaling in Adipocytes
2026-09-16
The reference study shows that trelagliptin succinate improves insulin-resistance phenotypes in differentiated 3T3-L1 adipocytes by enhancing IRS-1/AKT signaling, GLUT4 membrane localization, and glucose uptake while reducing free fatty acid and resistin release. Its experimental framework provides a useful model for connecting adipokine biology with phosphorylation-dependent insulin signaling, while also highlighting the need for carefully controlled pathway assays.
-
WAY-100635 Workflows for 5-HT1A Research
2026-09-16
WAY-100635 gives researchers a selective pharmacological control for separating 5-HT1A receptor signaling from broader pain, affective, and neuronal effects. This workflow connects receptor binding, functional antagonism, behavioral pharmacology, and imaging-oriented validation while emphasizing practical controls and troubleshooting.
-
Protease and Phosphatase Inhibitor Cocktail Guide
2026-09-15
Preserve both protein abundance and phosphorylation state during macrophage, tissue, and microbial lysate preparation with an EDTA-free 100X formulation. This workflow shows how to protect HMGB1-centered signaling assays while maintaining compatibility with experiments where metal chelation is undesirable.
-
Deferiprone Workflows for Iron-Stress Biology
2026-09-15
Build controlled iron-depletion experiments with Deferiprone for cancer biology, enterocyte metabolism, oxidative stress, and vascular models. This workflow combines dose optimization, time-resolved transcription, metabolic profiling, inflammatory challenge, and iron repletion to distinguish iron-specific effects from nonspecific toxicity.
-
Bradykinin BA5201: Reliable Cell Assay Workflows
2026-09-14
This scenario-driven guide explains how Bradykinin, SKU BA5201, can be integrated into endothelial, smooth-muscle, permeability, inflammation, and cell-viability workflows without confusing biological activity with assay toxicity. It covers experimental controls, exploratory parameters, peptide handling, interpretation, and practical vendor-selection criteria.
-
Hepatic sEH, Nrf2, and Osteoclastogenesis
2026-09-14
The reference study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppresses Nrf2-ARE signaling, and promotes osteoclast differentiation. By combining patient samples, an ovariectomy-induced osteoporosis model, liver-specific sEH knockdown, pharmacological inhibition, and transcriptomics, it provides a mechanistic framework for studying redox imbalance in bone remodeling.
-
RSL3 GPX4 Inhibitor: Ferroptosis Workflows
2026-09-13
RSL3 provides a direct way to test whether GPX4 dependence, iron accumulation, and lipid oxidation control cancer-cell survival. This practical guide connects ferroptosis assays with TEAD2 biology, oncogenic RAS synthetic lethality, and reproducible troubleshooting for cell and xenograft studies.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-12
This FASEB Journal study developed chemically modified CDKN1A/p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21 expression, altered cell-cycle and DNA-damage signaling, and reduced orthotopic tumor growth in mice while limiting systemic distribution.
-
DAPI Nuclear Stain Solution: Workflow Guide
2026-09-11
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution, SKU K2402, provides a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint cell viability assessment. It is most appropriate for fixed or membrane-compromised cells analyzed by fluorescence microscopy or flow cytometry, rather than routine imaging of intact live cells.
-
PF-573228: Reading FAK Signals in Stiff Matrices
2026-09-11
A translational framework for using PF-573228 to test whether substrate stiffness drives odontoblast differentiation through the LAMB1–FAK–MEK1/2 axis, while extending the logic to cancer and endothelial models.
-
SHH and FGF Control Penile Development Across Species
2026-09-10
A 2025 comparative study shows that species-specific penile development is associated with differences in Shh, Fgf10, and Fgfr2 expression, rather than being explained by anatomy alone. Its combination of spatial gene-expression analysis, quantitative PCR, and genital-tubercle culture identifies pathway dosage and timing as important determinants of prepuce and urethral groove formation.
-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-09-10
CDK9 inhibitor A3294 provides a selective serine/threonine kinase inhibitor for studying CDK9-dependent transcription elongation and HIV-1 propagation inhibition. It is intended for controlled biochemical and cellular assays, not pan-CDK experiments or long-term storage of prepared solutions.
-
Phosbind Acrylamide for Signaling Decisions
2026-09-09
A translational framework for using antibody-free mobility shifts to investigate phosphorylation-dependent regulation, illustrated through the RpfG–HtsH signaling architecture in Lysobacter enzymogenes.